News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

NPS Pharmaceuticals, Inc. (NPSP) to Present Data from Natpara™ REPLACE Study and PARADOX Study at ENDO 2013, the Endocrine Society’s 95th Annual Meeting



6/5/2013 7:02:23 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NPS Pharmaceuticals, Inc., a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide, today reported that two abstracts related to the Phase 3 REPLACE study of Natpara™ in hypoparathyroidism and one abstract related to PARADOX, a 374-patient epidemiology study that assessed the clinical, social, and economic implications of hypoparathyroidism will be presented at ENDO 2013, The Endocrine Society’s 95th Annual Meeting in San Francisco, June 15-18, 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES